

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RICI HEALTHCARE HOLDINGS LIMITED

瑞慈醫療服務控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1526)

VOLUNTARY ANNOUNCEMENT PROPOSED REPURCHASE OF SHARES PURSUANT TO THE SHARE REPURCHASE MANDATE

This announcement is made by Rici Healthcare Holdings Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company has been granted a general mandate by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company held on June 19, 2025 (the “**2025 AGM**”) to repurchase up to 10% of the total number of issued shares of the Company as at the date of the 2025 AGM (excluding any treasury shares of the Company) (the “**Share Repurchase Mandate**”).

The Board has passed a resolution to approve the repurchase of shares by the Company within the scope of the Share Repurchase Mandate with its own funds (excluding any proceeds raised from the listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), for a total repurchase amount not exceeding HK\$100 million (the “**Share Repurchase**”). The repurchase period shall commence from the date of the Board’s approval and end at the conclusion of the forthcoming annual general meeting of the Company to be held in 2026. The Company intends to hold the repurchased shares as treasury shares, which may in the future, as needed, be cancelled, sold, or transferred (including for transfer under an equity incentive scheme).

The Board has comprehensively considered the stability of the Company's current business operations, the sustainability of its financial profitability, its strong confidence in future development prospects, and the Company's stock market performance and valuation. The Board is of the view that the current market capitalisation of the Company's shares is below its intrinsic value. To effectively safeguard the value of the Company and the interests of all Shareholders, and to convey the management's confidence in the Company's long-term development, the Board proposes to implement the Share Repurchase.

The Board believes that the Share Repurchase not only reflects a high degree of recognition of the Company's intrinsic value but also demonstrates ample confidence in the long-term prospects of its business. This action will ultimately promote the recognition of the Company's value and create long-term and stable returns for the Shareholders, which is in the best interests of the Company and the Shareholders as a whole.

The Company will conduct the proposed Share Repurchase in compliance with the Company's Articles of Association, the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), the Codes on Takeovers and Mergers and Share Buy-backs, and all applicable laws and regulations. The proposed Share Repurchase will not result in the number of shares of the Company held by the public falling below the minimum public float requirement as stipulated under the Listing Rules. **Shareholders and potential investors should note that the Company will exercise the Share Repurchase Mandate subject to market conditions, and the exercise thereof is at the sole discretion of the Board. There is no fixed plan regarding the timing, number, or price of the Share Repurchase.**

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Rici Healthcare Holdings Limited
Fang Yixin
Chairman

Hong Kong, the PRC, May 20, 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Dr. Fang Yixin, Dr. Mei Hong, Mr. Fang Haoze and Ms. Lin Xiaoying; and three independent non-executive Directors, namely Mr. Jiang Peixing, Ms. Wong Sze Wing and Mr. Tian Wenguo.